Cellectar Biosciences, Inc. reported results
SEC 8-KRead source ↗
Cellectar Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$2.9
Forward price-to-sales vs peers
Base case. Range ~$2.9–$11. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Cellectar Biosciences, Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 1 selling2 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
- Funds19 adding, 6 cuttingOf 6 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Free cash flow diverging from earnings: TTM free cash flow grew 43.7% while net income grew 23.2%: a 20pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Cellectar Biosciences, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 78% and a beta of 1.6 against the S&P 500.
Latest results
- Earnings per share
- -$0.57 against an average estimate of -$0.52: missed by 9.6%
- Share reaction
- 0.0% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
- Next report
- November 12, 2026; average EPS estimate -$0.56
Price chart
- 1 day+0.8%
- 1 week+0.8%
- 1 month-31.5%
- This year-58.6%
- 1 year-64.0%
- 5 years-99.6%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 13, 2026
- Next results (est.)
- November 12, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
Valuation models
We value Cellectar Biosciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.19 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$2.9 ~$2.9–$11 | Included, half weight |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$2.9 ~$2.9–$11 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cellectar Biosciences, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026. Analysts expect revenue of $0 and EPS of −$0.56 (range −$0.77 to −$0.42) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$2.43 | +71% | — | 0% |
| Next | −$1.92 | +21% | $8m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +12.1% on 90 days ago. In the last 30 days, 2 analysts raised Cellectar Biosciences, Inc.'s forecast and 2 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$2.17 | −$1.79 |
| 60 days ago | −$2.43 | −$1.92 |
| 30 days ago | −$2.43 | −$1.92 |
| 7 days ago | −$2.43 | −$1.92 |
| Now | −$2.43 | −$1.92 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.52 | −$0.57 | −9.6% |
| Mar 2026 | −$1.89 | −$1.33 | +29.4% |
| Dec 2025 | −$1.23 | −$0.53 | +56.7% |
| Sept 2025 | −$2.53 | −$1.41 | +44.2% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 2.8% of tradable shares
- Days to cover
- 1.95 at average volume
- Short interest, 1 month
- +38% to October 15, 2026
- Held by institutions
- 35% of shares
- Held by insiders
- 1.8% of shares
- Employees
- 11 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| CLRB | −68% | −74% | +62% | −89% | −67% | −59% |
| Industry peers (median) | −35% | −56% | −18% | −28% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| CLRB | 8% | 17% | 58% | 33% | 50% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| CLRB | −76% | −84% | −33% | −94% | −81% | −72% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from November 2, 2015 to October 19, 2026. Getting back needed a 5089186% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $1.12 – $4.04
- From 52-week high
- −69.8%
- vs 50-day average
- −34.3%
- vs 200-day average
- −53.5%
- Volatility (1 year)
- 78%
- Beta vs S&P 500
- 1.65
Share price after results
- Next day
- 5 up, 7 down typical move ±7.6%
- After a week
- 6 up, 6 down typical move ±10.5%
- After a month
- 4 up, 8 down typical move ±25.7%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 13, 2026 | 0.0% | +0.5% | −0.4% | −11.2% |
| May 14, 2026 | +5.1% | −0.4% | +7.8% | −20.4% |
| March 4, 2026 | +3.4% | +0.1% | +10.4% | −4.9% |
| November 13, 2025 | −17.1% | −1.7% | −19.4% | −8.6% |
| October 10, 2025 | +2.5% | −1.2% | −5.7% | −25.8% |
| August 14, 2025 | −1.8% | −0.2% | +1.6% | +16.5% |
| May 13, 2025 | −7.7% | +0.8% | 0.0% | +69.2% |
| March 13, 2025 | 0.0% | +0.7% | +18.8% | −12.5% |
| November 18, 2024 | −13.4% | +0.8% | −15.6% | −86.6% |
| August 13, 2024 | +7.5% | +2.0% | +11.8% | +13.4% |
| July 23, 2024 | −22.5% | −2.4% | −28.8% | −29.1% |
| May 14, 2024 | +9.8% | +1.7% | +6.2% | +9.8% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $9.7M
- Institutions reporting
- 29
- Shares held vs prior quarter
- ▲ 1019.9%
- Positions opened / closed
- 13 / 4
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Caligan Partners LP | $1.3M | 470K | 13.5% | New |
| Nantahala Capital Management, LLC | $1.2M | 440K | 12.6% | New |
| Stempoint Capital LP | $986,728 | 355K | 10.2% | New |
| Vanguard Capital Management LLC | $910,080 | 327K | 9.4% | ▲ 299.8% |
| Silverarc Capital Management, LLC | $894,404 | 322K | 9.2% | New |
| Bleichroeder LP | $802,528 | 289K | 8.3% | ▲ 188.7% |
| Jupiter Topco LLC | $759,412 | 274K | 7.8% | — |
| Balyasny Asset Management L.P. | $611,600 | 220K | 6.3% | New |
| Empery Asset Management, LP | $527,102 | 190K | 5.4% | New |
| Diadema Partners LP | $384,588 | 138K | 4.0% | New |
| Stonepine Capital Management, LLC | $290,649 | 105K | 3.0% | New |
| Persistent Asset Partners Ltd | $258,493 | 93K | 2.7% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cellectar Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $49,997 2 trades by 2 insiders, last 12 months Insider sales History → $733 1 trade by 1 insider · 0% under pre-set plans
Net ▲ $49,264 net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Caruso James V Chief Executive Officer | May 7, 2026 | Buy | 8,680 | $2.88 | $24,998 |
| Longcor Jarrod Chief Operating Officer | May 7, 2026 | Buy | 8,680 | $2.88 | $24,998 |
| Neis John Director | December 12, 2025 | Sell | 198 | $3.70 | $733 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced
- August 13, 2026
- May 14, 2026
- March 4, 2026
- November 13, 2025
- October 10, 2025
- August 14, 2025
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- S-1 FORM S-1
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Cellectar Biosciences, Inc. in brief
- What does Cellectar Biosciences, Inc. do?
- Cellectar Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Cellectar Biosciences, Inc.'s stock ticker?
- Cellectar Biosciences, Inc. trades under the ticker CLRB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Cellectar Biosciences, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Caligan Partners LP, Nantahala Capital Management, LLC and Stempoint Capital LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Cellectar Biosciences, Inc. stock?
- Over the last 12 months, Cellectar Biosciences, Inc.'s directors and officers reported 2 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
- When is Cellectar Biosciences, Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cellectar Biosciences, Inc. announces its own schedule.
Follow research on Cellectar Biosciences, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.